# Multiplexing methods to reduce sequencing costs

> **NIH NIH R44** · CORAL GENOMICS, INC. · 2021 · $1,205,206

## Abstract

PROJECT SUMMARY
Next-generation sequencing (NGS) technology has enabled significant discoveries and clinical applications from
genotype data. In particular, rapid shallow whole genome sequencing (WGS) and whole exome sequencing
(WES) has the capacity to revolutionize healthcare interventions. The demand for shallow WGS and WES has
exploded and is expected to continue to increase. However, despite the advancements in instrumentation, the
marginal cost of shallow WGS and WES has plateaued due to inefficient methods of sample preparation and
simplistic approaches to sample pooling. Moreover, the turnaround time of several weeks for sequencing results
presents a significant barrier for wide adoption of the technology for clinical purposes.
Coral Genomics is developing a new rapid shallow sequencing technology for massively parallel WGS and WES,
providing clinically relevant predictions within hours of sequencing completion. We have developed a new
sample pooling approach capable of sequencing hundreds of samples with less than 1 week of wait time. With
our approach, we have reduced sequencing costs by 50%. With continued development of our library preparation
strategy, we expect to further increase the scale of sample processing while also further reducing costs. We
have also developed a real-time analysis platform capable of returning variant calls within 2 hours of sequencing
completion. Our proprietary dataset associating genetic variations to drug response predictions, developed in-
house, is the largest in existence and has led to several new polygenic predictions. With this dataset and our
synergistic technologies, we are in the unique position to develop a platform for extremely rapid feedback
on clinical samples on a large scale at significantly reduced cost. We expect to bring the cost of shallow
coverage WGS and WES down to $15 or less per sample, while providing extremely rapid turnaround times.
Specifically, we have a strong foundation for identifying polygenic-score based indications for inflammatory bowel
disease, pain medications, and coronary artery disease, and predicting optimal therapeutic intervention in these
cases.
Successful completion of this project will produce a commercially viable and highly competitive NGS
service that is positioned to revolutionize personalized health care.

## Key facts

- **NIH application ID:** 10262952
- **Project number:** 5R44HG010445-03
- **Recipient organization:** CORAL GENOMICS, INC.
- **Principal Investigator:** Atray Dixit
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,205,206
- **Award type:** 5
- **Project period:** 2019-09-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10262952

## Citation

> US National Institutes of Health, RePORTER application 10262952, Multiplexing methods to reduce sequencing costs (5R44HG010445-03). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10262952. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*